Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 1, 2012, Pages 69-77

  Wu, Ming Ju ^a,b,c,d   Chang, Chi Hao ^c,d   Chiu, Yung Tsung ^a   Wen, Mei Chin ^a   Shu, Kuo Hsiung ^a,b   Li, Jian Ri ^a   Chiu, Kun Yuan ^a   Chen, Yen Ta ^e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

AKT; Rapamycin; Rictor; Urothelial carcinoma; VEGF

Indexed keywords

CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CARRIER PROTEINS; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MALE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, INBRED F344; SIROLIMUS; URINARY BLADDER NEOPLASMS;

EID: 84855710576     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.11.009     Document Type: Article

References (33)

1. Vajdic C.M., McDonald S.P., McCredie M.R.E., et al. Cancer incidence before and after kidney transplantation. JAMA 2006, 296:2823-2831.
2. Geissler E.K., Schlitt H.J., Thomas G. mTOR, cancer, and transplantation. Am J Transplant 2008, 8:2212-2218.
3. Webster A.C., Wong G., Craig J.C., et al. Managing cancer risk and decision making after kidney transplantation. Am J Transplant 2008, 8:2185-2191.
4. Dantal J., Pohanka E. Malignancies in renal transplantation: An unmet medical need. Nephrol Dial Transplant 2007, 22(Suppl 1):i4-i10.
5. Tsang C.K., Qi H., Liu L.F., et al. Targeting mammalian target of rapamycin for health and disease. Drug Discov Today 2007, 12:112-114.
6. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271-280.
7. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephro 2006, 17:581-589.
8. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883-889.
9. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281.
10. Wu M.J., Lian J.D., Yang C.R., et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004, 43:1091-1097.
11. Hung Y.M., Chou K.J., Hung S.Y., et al. De novo malignancies after kidney transplantation. Urology 2007, 69:1041-1044.
12. Chiang Y.J., Wang H.H., Liu K.L., et al. Hepatocellular carcinoma following renal transplantation: Experience in northern Taiwan. Transplant Proc 2008, 40:2397-2399.
13. Tian Y., Xiao J., Du L.D., et al. Clinical study of 44 cases of urological malignant tumors following kidney transplantation. Chin J Organ Transplant 2007, 28:417-419.
14. Zhou M.S., Zhu Y.H., Wang L.M., et al. Malignant tumor of urinary system in renal allograft recipients in one center. Chin J Organ Transplant 2007, 28:624-626.
15. Wu M.J. The role of mTOR inhibitors in renal disease. Acta Nephrologica 2008, 22:209-210.
16. Lin J., Tian Y., Tang Y.W., et al. Nine cases of conversion from calcineurin inhibitor to sirolimus in the treatment of urological neoplasm in kidney allograft recipients. Chin J Organ Transplant 2007, 28:205-207.
17. Hattori K., Iida K., Joraku A., et al. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006, 97:640-643.
18. Wu M.J., Wen M.C., Chiu Y.T., et al. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006, 69:2029-2036.
19. Boffa D.J., Luan F., Thomas D., et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004, 10:293-300.
20. Luan F.L., Hojo M., Maluccio M., et al. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002, 73:1565-1572.
21. Pinto-Leite R., Botelho P., Ribeiro E., et al. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res 2009, 28:3.
22. Guba M., Breitenbuch P.V., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nature Med 2002, 8:128-135.
23. Amornphimoltham P., Patel V., Sodhi A., et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005, 65:9953-9961.
24. Decker T., Hipp S., Ringshausen I., et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003, 101:278-285.
25. Di Paolo S., Teutonico A., Leogrande D., et al. Chronic inhibition of mammalian target of rapamycin signaling down-regulated insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes?. J Am Soc Nephrol 2006, 17:2236-2244.
26. Breuleux M., Klopfenstein M., Stephan C., et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009, 8:742-753.
27. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 2006, 66:1500-1508.
28. Sun S.Y., Rosenberg L.M., Wang X., et al. Activation of AKT and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65:7052-7058.
29. Zhang H., Bajraszewski N., Wu E., et al. PDGFRs are critical for PI3K/AKT activation and negatively regulated by mTOR. J Clin Invest 2007, 117:730-738.
30. Sarbassov D.D., Ali S.M., Sengupta S., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and ATK/PKB. Mol Cell 2006, 22:159-168.
31. Abraham R., Gibbons J.J. The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13:3109-3114.
32. Wan X., Harkavy B., Shen N., et al. Rapamycin induces feedback activation of AKT signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940.
33. Fan Q.W., Knight Z.A., Goldenberg D.D., et al. A dual PI3 Kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006, 9:341-349.